EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Health-Related Quality of Life Outcomes With Etrasimod Treatment in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From ELEVATE UC 52 and ELEVATE UC 12

Alessandro Armuzzi, David T Rubin, Stefan Schreiber, Julian Panés, Marc Fellmann iD, Lauren Bartolome, David Gruben, Martina Goetsch, Abhishek Bhattacharjee, María Chaparro, Marla C Dubinsky iD

Inflammatory Bowel Diseases · 13.06.2025 · 31 (6) · 1583-1594

DOI: 10.1093/ibd/izae229 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 26.09.2024. Verfasst von Alessandro Armuzzi und 10 weiteren Autor:innen. Beteiligte Einrichtung: IBD Unit, IRCCS Humanitas Research Hospital, Milan, Italy. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Quality of Life, Sphingosine 1 Phosphate Receptor Modulators. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Etrasimod is an oral, once-daily (QD), selective sphingosine 1-phosphate1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). Here, we evaluate the impact of etrasimod 2 mg QD on health-related quality of life (HRQoL) in patients with UC.

Methods

This post hoc analysis used data from the Phase 3 randomized controlled trials, ELEVATE UC 52 and ELEVATE UC 12. HRQoL measures included: Inflammatory Bowel Disease Questionnaire (IBDQ), 36-Item Short Form Survey (SF-36), and Work Productivity and Activity Impairment Questionnaire: Ulcerative Colitis (WPAI:UC) completed at baseline, Week 12 (both trials), and Week 52 (ELEVATE UC 52 only). For IBDQ analyses, patients were stratified by prior exposure to biologics/Janus kinase inhibitors (JAKi) and baseline modified Mayo score (MMS; 4-6 or 7-9).

Results

Generally, significantly greater proportions of patients receiving etrasimod (N = 527) vs placebo (N = 260) achieved IBDQ remission (IBDQ total score ≥170) and IBDQ response (IBDQ total score increase from baseline ≥16), with significant improvement in all IBDQ domain scores at Week 12 and maintained through Week 52. Significant differences in IBDQ remission and IBDQ response rates between etrasimod and placebo were more consistent among biologic/JAKi-naive patients vs those who were biologic/JAKi-experienced and in those with baseline MMS 7-9 vs 4-6. Significant improvements were observed in several SF-36 domain and summary scores and WPAI:UC domain scores at Week 12 and Week 52.

Conclusions

Etrasimod 2 mg QD demonstrated significant and clinically meaningful improvements across multiple HRQoL measures, including WPAI, vs placebo. Clinical Trial Registration ClinicalTrials.gov: NCT03945188; NCT03996369

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeQuality of LifeSphingosine 1 Phosphate Receptor ModulatorsAdultFemaleHumansMaleMiddle AgedDouble-Blind MethodSeverity of Illness IndexSurveys and QuestionnairesTreatment Outcome

Stichwörter der Autor:innen

etrasimodhealth-related quality of lifesphingosine 1-phosphate receptor modulatorulcerative colitis

Substanzen

Sphingosine 1 Phosphate Receptor Modulators

Autor:innen und Institutionen

  • IBD Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
  • Department of Biomedical Sciences, Humanitas University, Milan, Italy.
  • University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, USA.
  • Department of Internal Medicine I, University Hospital Schleswig-Holstein, Kiel University, Kiel, Germany.
  • Formerly Department of Gastroenterology, Hospital Clínic de Barcelona, IDIBAPS, Centro de Investigacíon Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain.
  • Pfizer AG, Zürich, Switzerland.

ORCID-Profile: Marc Fellmann, Marla C Dubinsky

Förderung

  • Pfizer

Zitieren

APA

Armuzzi, A., Rubin, D. T., Schreiber, S., Panés, J., Fellmann, M., Bartolome, L., Gruben, D., Goetsch, M., Bhattacharjee, A., Chaparro, M., & Dubinsky, M. C. (2025). Health-Related Quality of Life Outcomes With Etrasimod Treatment in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From ELEVATE UC 52 and ELEVATE UC 12. Inflammatory Bowel Diseases, 31(6), 1583-1594. https://doi.org/10.1093/ibd/izae229

Vancouver

Armuzzi A, Rubin DT, Schreiber S, Panés J, Fellmann M, Bartolome L, et al. Health-Related Quality of Life Outcomes With Etrasimod Treatment in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From ELEVATE UC 52 and ELEVATE UC 12. Inflammatory Bowel Diseases. 2025;31(6):1583-1594. doi:10.1093/ibd/izae229

BibTeX
@article{Armuzzi2025,
  author = {Armuzzi, Alessandro and Rubin, David T and Schreiber, Stefan and Panés, Julian and Fellmann, Marc and Bartolome, Lauren and Gruben, David and Goetsch, Martina and Bhattacharjee, Abhishek and Chaparro, María and Dubinsky, Marla C},
  title = {Health-Related Quality of Life Outcomes With Etrasimod Treatment in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From ELEVATE UC 52 and ELEVATE UC 12},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  volume = {31},
  number = {6},
  pages = {1583--1594},
  doi = {10.1093/ibd/izae229}
}
Kostenlos starten →